newwin
Luciann Nguyen
Settings
← Accounts
biotech

Auricula Biosciences Inc.

42
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

Auricula Biosciences Inc.

New trial — Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

New trialNCT07148128
42/100
Opportunity
Commercial fit5/25
Clinical timing20/20
Biomarker need0/20
Relationship2/10
Signal strength9/10
Account value5/10
Urgency1/5

New phase 1_2 trial NCT07148128 posted by Auricula Biosciences Inc.: "Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.". New trial on a phase 1_2 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 222 days ago.

ConfidenceHigh · 80%clinical development · translational medicine · clinical operations
Draft outreachReview

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

TrialPhaseTesting language
NCT07148128
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
phase 1 2
—